Enliven Therapeutics, Inc. (ELVN) Earnings History
Net Loss9 years of earnings data (2017–2025) · Currently unprofitable on a TTM basis
Loading earnings history...
Enliven Therapeutics, Inc. (ELVN) Earnings Overview
As of June 23, 2026, Enliven Therapeutics, Inc. (ELVN) reported trailing twelve-month net income of -$99M, reflecting +3.2% year-over-year growth. The company earned $-1.57 per diluted share over the past four quarters.
Looking at the long-term picture, ELVN's historical earnings data spans multiple years. The company achieved its highest annual net income of $0 in fiscal 2017.
Enliven Therapeutics, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including KYMR (-$315M net income, -794.4% margin), RVMD (-$1.37B net income), IMVT (-$506M net income), ELVN has comparable earnings metrics. Compare ELVN vs KYMR →
ELVN Earnings vs Peers
Earnings metrics vs comparable public companies
ELVN Historical Earnings Data (2017–2025)
9 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$104M | -16.5% | -$120M | $-1.83 | - | - |
| 2024 | -$89M | -24.4% | -$105M | $-1.89 | - | - |
| 2023 | -$72M | -90.1% | -$84M | $-2.01 | - | - |
| 2022 | -$38M | -52.2% | -$39M | $-6.03 | - | - |
| 2021 | -$25M | -30.4% | -$25M | $-3.17 | - | - |
| 2020 | -$19M | +19.2% | -$9M | $-4.31 | - | - |
| 2019 | -$23M | -107.0% | -$24M | $-5.43 | - | - |
| 2018 | -$11M | - | -$11M | $-2.62 | - | - |
| 2017 | $0 | - | -$9M | $0.00 | - | - |
Download Data
Export ELVN earnings history in CSV or JSON format
Free sign-in required to download data
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
9+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
ELVN — Frequently Asked Questions
Quick answers to the most common questions about buying ELVN stock.
What is ELVN earnings per share (EPS)?
ELVN trailing twelve-month (TTM) diluted EPS is $-1.57, reflecting +3.2% year-over-year growth. The 5-year EPS CAGR is N/A. Complete EPS history from 2017 to 2025 is available in the table on this page.
What is Enliven Therapeutics, Inc.'s net income?
Enliven Therapeutics, Inc. (ELVN) trailing twelve-month net income is $-99M as of 2025. Earnings grew +3.2% year-over-year.
Is ELVN profitable?
ELVN is not currently profitable on a TTM basis, reporting a net loss of $-99M. Net margin is N/A. Investors should monitor for a return to profitability.
What is ELVN's earnings growth rate?
ELVN compound annual EPS growth rates (CAGR): 1-Year: N/A, 3-Year: N/A, 5-Year: N/A, 10-Year: N/A. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 2017 to 2025.
What are ELVN's profit margins?
Enliven Therapeutics, Inc. net profit margin is N/A, operating margin is N/A, and gross margin is N/A. Below-average margins reflect competitive or cost pressures. Return on Equity is -27.0%.
Is ELVN growing earnings?
ELVN earnings growth is slowing. Current YoY EPS growth of +3.2% trails the 5-year CAGR of N/A. TTM net income is $-99M.
What was ELVN's best earnings year?
Enliven Therapeutics, Inc.'s highest annual net income on record is $0.00, achieved in fiscal year 2017. Earnings history on this page spans 2017 to 2025 and includes all annual and quarterly figures.
What were ELVN's earnings last quarter?
ELVN's most recent reported quarter was Q1 2026. Net income was $-24M with diluted EPS of $-0.38. For a full breakdown of all quarters, see the quarterly earnings table on this page.